Precision Medicine and New Treatments for Moderate to Severe Asthma (PrecISE)
PrecISE, the Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network, is a research study to understand how to treat different types of severe asthma. We are looking for people who have asthma attacks or frequent asthma symptoms. Everyone in the study will receive one or more study medicines for their severe asthma. This study is sponsored by the U.S. National Heart, Lung, and Blood Institute (NHLBI). This study is designed to investigate new treatments for asthma that are thought to work better in some patients than in others. The data from this research study will be used to determine which treatments work and what kind of patient benefits the most from that treatment.
Study phase: II
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
PrecISE is a multi-site study, sponsored by the National Heart, Lung, and Blood Institute. We are inviting people to participate in PrecISE who: 1) are age 12 or older, 2) meet guideline criteria for severe asthma, 3) currently have uncontrolled asthma, or continue to have exacerbations (attacks), and 4) are on a stable regimen of asthma medications (controller/daily medication).
Additional information:
• Participants will be compensated for completing study activities.
Primary disease category: Asthma & Lung
Secondary disease categories: Allergy & Immunology
This study is enrolling healthy volunteers.
Sponsor: National Heart, Lung, and Blood Institute
Protocol number: PRECISE Therapy
Projected enrollment dates: December 2019 to June 2023
Official study title: PrecISE: Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network
External link(s):
PRECISE Asthma
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT#04129931